Beam Therapeutics Inc. (BEAM) News

Beam Therapeutics Inc. (BEAM): $84.59

-3.87 (-4.37%)

POWR Rating

Component Grades













Add BEAM to Watchlist
Sign Up

Industry: Biotech


of 486

in industry

Filter BEAM News Items

BEAM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BEAM News Highlights

  • 500 - Internal server error
  • Over the past 18 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • GENE, BIO and GHVI are the most mentioned tickers in articles about BEAM.

Latest BEAM News From Around the Web

Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

The 7 Best Cryptos to Buy for Privacy

Cryptos are one of the hottest investment trends right now, but not everyone makes the cut on the privacy end due to regulatory pressure.

Faizan Farooque on InvestorPlace | June 7, 2021

2 Winners for a Drug Development Future That Looks Nothing Like the Past

In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years.

Yahoo | June 4, 2021

Beam Therapeutics: INDs This Year

Photo by BlackJack3D/E+ via Getty Images Last time we saw, Beam Therapeutics (BEAM) was planning a "wave" of INDs beginning in 2021. Now that we are in the middle of 2021, we want to see what they have been up to. Beam Therapeutics, if you recall, is a $4.4bn recent...

Avisol Capital Partners on Seeking Alpha | May 27, 2021

Beam Therapeutics Is Ready to Beam Higher

Beam Therapeutics is pioneering the use of base editing - a potential new class of precision genetic medicines. This is way above my pay grade so let's look at the charts of BEAM. In this daily bar chart of BEAM, below, we can see that prices made a base in the $20-$30 area before rallying to a high in February above $120.

Yahoo | May 26, 2021

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET.

GlobeNewswire | May 25, 2021

3 Growth Stocks to Buy That Could Be Bigger Winners Than Bitcoin and Dogecoin

Bitcoin (CRYPTO: BTC) and Dogecoin (CRYPTO: DOGE) -- are down more than 40% from their highs set earlier this year. Here are three growth stocks to buy that could easily be bigger winners than Bitcoin and Dogecoin. Gores Holdings VI (NASDAQ: GHVI) shares are currently down more than 40% from the peak in February.

Yahoo | May 24, 2021

Prime Editing Technology Market to See Major Growth by 2026 : Horizon Discovery, Beam Therapeutics, Inscripta, Precision BioSciences

Edison, NJ -- ( SBWIRE ) -- 05/17/2021 -- A new research document released by HTF MI with title "Global Prime Editing Technology Market Trend Anslysis & Growth 2021-2026" provides a complete assessment of Prime Editing Technology Market. The study focuses on changing market dynamics, geopolitical and regulatory policies, key players Strategies to better analyse demand at risk across various product type. Some of the major and emerging players analysed in the study are Beam Therapeutics, Inscripta, Precision BioSciences, Sangamo Therapeutics, Horizon Discovery, CRISPR Therapeutics, GenScript, Intellia Therapeutics & Synthego Corporation etc. Access Sample Copy of Prime Editing Technology Market Report @:

SBWire | May 17, 2021

Beam Therapeutics (NASDAQ:BEAM) Shares Down 8.2% After Earnings Miss

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) dropped 8.2% on Monday following a dissappointing earnings announcement. The stock traded as low as $64.69 and last traded at $64.99. Approximately 2,073 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 1,034,089 shares. The stock had previously closed at $70.82. The []

Dakota Financial News | May 12, 2021

Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners

Beam Therapeutics Inc (NASDAQ: BEAM ) reported a wider Q1 net loss of $201.6 million compared to $31.7 million a year ago, on higher R&D costs of $190.1 million, up from $21.5 million in Q1 2020. It includes $155 million of expense related to in-process research and development acquired from Guide Therapeutics Inc in February this year. Beam ended Q1 with cash and equivalents of $503.5 million. The company also presented data at ASGCT on its proprietary lipid nanoparticle (LNP) formulation showing efficient in vivo base editing in hepatocytes of non-human primates (NHPs). Beam evaluated various LNP formulations and … Full story available on

Benzinga | May 11, 2021

Rocket Pharma Stock Drops After FDA Institutes Clinical Hold On RP-A501 Danon Disease Trial

View more earnings on RCKTSee more from BenzingaClick here for options trades from BenzingaBeam Therapeutics Takes 5M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn PartnersLilly, MiNA Ink Broad RNA Deal Worth .25B© 2021 Benzinga does not provide investment advice. All rights reserved.

Yahoo | May 11, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6633 seconds.